What Ampio Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Buchi J Kevin | Director | Jun 09 | Open-market buy · P | +21,858 | $0.29 | +$6.28K | 146,858 |
| Buchi J Kevin | Director | Jun 08 | Open-market buy · P | +25,000 | $0.30 | +$7.4K | 125,000 |
| Martino Michael A | CEO | May 24 | Open-market buy · P | +76,890 | $0.29 | +$22.1K | 76,890 |
| Buchi J Kevin | Director | May 16 | Open-market buy · P | +32,534 | $0.27 | +$8.92K | 100,000 |
| Buchi J Kevin | Director | May 15 | Open-market buy · P | +44,026 | $0.25 | +$10.9K | 67,466 |
| Buchi J Kevin | Director | May 12 | Open-market buy · P | +23,440 | $0.24 | +$5.51K | 23,440 |
| Stevens David R | Director | May 12 | Open-market buy · P | +45,000 | $0.22 | +$9.9K | 103,971 |
| Stevens David R | Director | May 11 | Open-market buy · P | +25,000 | $0.22 | +$5.38K | 58,971 |
| Stevens David R | Director | May 11 | Open-market buy · P | +25,000 | $0.22 | +$5.5K | 33,971 |
| Macaluso Michael | Director | Jan 01 | Withheld — tax / exercise cost · F | −68,400 | $0.57 | −$39K | 2,624,882 |
| Cherevka Holli | PRESIDENT AND COO | Jan 01 | Withheld — tax / exercise cost · F | −47,200 | $0.57 | −$26.9K | 410,820 |
| Stokely Dan | CFO | Jan 01 | Withheld — tax / exercise cost · F | −22,914 | $0.57 | −$13.1K | 312,274 |
| Cherevka Holli | PRESIDENT AND COO | Oct 27 | Withheld — tax / exercise cost · F | −41,980 | $1.64 | −$68.8K | 458,020 |
| Macaluso Michael | CEO | Oct 27 | Withheld — tax / exercise cost · F | −43,470 | $1.64 | −$71.3K | 2,693,282 |
| Stokely Dan | CFO | Oct 27 | Withheld — tax / exercise cost · F | −28,127 | $1.64 | −$46.1K | 335,188 |
| Cherevka Holli | CHIEF OPERATING OFFICER | Oct 11 | Grant / award · A | +500,000 | — | — | 500,000 |
| Stokely Dan | CFO | Oct 11 | Grant / award · A | +335,000 | — | — | 363,315 |
| Macaluso Michael | CEO | Oct 11 | Grant / award · A | +950,000 | — | — | 2,736,752 |
| Stokely Dan | CFO | Jun 25 | Open-market sale · S | −22,500 | $1.79 | −$40.3K | 28,315 |
| Stokely Dan | CFO | Jun 25 | Exercise / conversion · M | +22,500 | $0.43 | +$9.68K | 50,815 |
Loading...
